TD Cowen downgraded Baxter from Buy to Hold and set a new price target of $40.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2025 | $39.00 | Overweight | Barclays |
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
| 5/30/2024 | $36.00 | Neutral | Goldman |
| 5/10/2024 | $40.00 | Buy → Hold | TD Cowen |
| 5/30/2023 | $45.00 | Equal-Weight | Morgan Stanley |
| 3/29/2023 | $43.00 | Neutral | UBS |
| 1/6/2023 | $55.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2023 | Outperform → Mkt Perform | Raymond James |
Barclays resumed coverage of Baxter with a rating of Overweight and set a new price target of $39.00
Morgan Stanley downgraded Baxter from Equal-Weight to Underweight and set a new price target of $30.00 from $39.00 previously
Goldman initiated coverage of Baxter with a rating of Neutral and set a new price target of $36.00
Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceeding the company's previously issued guidance1 Fourth-quarter U.S. GAAP2 diluted earnings per share (EPS) (loss) from continuing operations of ($0.95); adjusted diluted EPS from continuing operations of $0.58, exceeding the company's previously issued guidance Full-year sales from continuing operations of $10.64 billion increased 3% on both a reported and constant currency basis, exceeding the company's previously issued guidance Full-year U.S. GAAP diluted EPS (loss) from continuing operations of ($0.64); adjusted diluted EPS from continuing ope
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on April 1, 2025, to stockholders of record as of Feb. 28, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where inn
José (Joe) E. Almeida to retire as Chair, President and Chief Executive Officer Lead Independent Director Brent Shafer appointed Chair and Interim CEO Board has initiated a comprehensive search to select full-time replacement Heather Knight appointed Chief Operating Officer Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025. The Baxter Board of Directors has appointed lead independent director Brent Shafer as chair and interim CEO and
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, Brian Stevens, who has served as the company's interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller. "Joel is a seasoned global financial executive with decades of deep operational and broad business experience as well as a proven record of results-driven impact," said Mr. Almeida. "I am confident we will benefit from Joel's leadership
Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceeding the company's previously issued guidance1 Fourth-quarter U.S. GAAP2 diluted earnings per share (EPS) (loss) from continuing operations of ($0.95); adjusted diluted EPS from continuing operations of $0.58, exceeding the company's previously issued guidance Full-year sales from continuing operations of $10.64 billion increased 3% on both a reported and constant currency basis, exceeding the company's previously issued guidance Full-year U.S. GAAP diluted EPS (loss) from continuing operations of ($0.64); adjusted diluted EPS from continuing ope
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:10 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, September 1, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Monday, March 3, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:05 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Saturday, August 30, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. F
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
SCHEDULE 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
8-K/A - BAXTER INTERNATIONAL INC (0000010456) (Filer)